OR WAIT null SECS
April 29, 2023
Article
At ARVO 2023, 24-month data suggests the change from baseline in GA lesion growth consistently favored pegcetacoplan vs. sham across subgroups in DERBY and OAKS trials.
April 24, 2023
Video
In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.
At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.
April 23, 2023
Podcast
As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.
January 22, 2023
Eyes treated with pegcetacoplan showed a significantly slower GA lesion progression rate compared with sham, and slower growth rate toward the fovea.